Zimbabwe has declined a substantial American health deal valued at $367m (£272m) spanning five years because of Washington's request for sensitive data.
The decision came to light following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman later clarified that the United States was demanding access to genetic material for research and profit while was not willing to guarantee the benefits from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for further dialogue to find a deal acceptable to all parties so the nation's vital HIV programme can proceed.
Wider Context
Zimbabwe's decision comes after a similar situation in Kenya, where a court halted a related health funding agreement following concerns were raised about the safety of citizens' medical information.
After resuming office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government agreements to boost openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to these new agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our people if a future pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral deals were undermining structures already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future co-operation could be structured in a way that honours the independence and interests of each country."
Medical Community Reaction
A leading public health body said it understood the government's concerns, but suggested that negotiations should continue since a large portion of the country's Aids initiatives relied on external financing.
"If specific concerns arise, including those involving information security or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group said.
The halted deal emphasises the ongoing tensions between accepting crucial international aid and protecting a country's data in an ever more data-driven world.